New progestogens in oral contraceptives.

Area of Science:

• Endocrinology
• Pharmacology
• Gynecology

Background:

• Oral hormonal contraceptives (OCs) aim for improved metabolic and endometrial effects.
• Existing formulations include ethinyl estradiol with levonorgestrel or desogestrel.
• Newer synthetic progestogens like gestodene and norgestimate are being evaluated.

Purpose of the Study:

• To compare the metabolic and hemostatic effects of new OCs containing gestodene or norgestimate with existing formulations.
• To assess the impact on glucose metabolism, lipid profiles, and blood coagulation.
• To evaluate potential long-term benefits regarding cardiovascular side effects and menstrual cycle control.

Main Methods:

• Comparative study of low-dose oral contraceptive pills.
• Administration of glucose loading tests to assess serum glucose and insulin levels.
• Analysis of lipid metabolism, including total cholesterol, HDL cholesterol, and triglycerides.
• Evaluation of blood coagulation parameters.

Main Results:

• No significant alterations in serum glucose levels were observed after glucose loading with any of the tested OCs.
• Slightly elevated insulin levels were noted with all four combination pills compared to controls.
• Progestogens demonstrated varied effects on lipid metabolism; new progestogens showed a more pronounced effect on triglycerides.
• Total cholesterol and HDL cholesterol remained largely unchanged.
• Low-dose OCs, including new formulations, had minimal impact on blood coagulation.

Conclusions:

• New synthetic progestogens in low-dose OCs appear to have a favorable metabolic profile, with minimal effects on glucose and lipid metabolism.
• These formulations are expected to offer benefits for cardiovascular health and menstrual cycle regulation in long-term use.
• Low-dose monophasic and triphasic OCs containing new progestogens are promising for long-term contraceptive therapy.